Abstract: Drug-loaded microbead compositions include microbeads of a water-swellable polymer material and a complex of a carrier and a therapeutic agent chemically bonded to the carrier. The complex is embedded in the polymer material. Methods for preparing the drug-loaded microbead compositions and embolization compositions include loading a therapeutic agent into a water-swellable polymer material to form microbeads, then removing water from the microbeads. Additional drug-loaded microbead compositions include microbeads of a biodegradable material, vesicular agents, a first therapeutic agent associated with the vesicular agents, and a second therapeutic agent different from the first therapeutic agent. The vesicular agents include a lipid bilayer surrounding a vesicular core. The second therapeutic agent is contained within the microbeads or associated with the microbeads through ionic or non-covalent interaction and may or may not be associated with the vesicular agents.

Abstract: In some implementations, a system may receive, from a first user, data associated with a new database entry to be added to a master database that is associated with multiple sets of users having different access permissions to entries in the master database. The system may write the data to a first repository, write an entry including the data to a master repository, and generate a record of the entry. The system may receive, from a second user, additional data associated with the new database entry. The system may write the additional data to a second repository, modify the entry in the master repository based on the additional data, and generate a record of the modified entry. The system may perform verifications and output a notification based on the verifications. The system may further output, to a public repository, the modified entry with at least one data value removed.

Abstract: Drug-loaded microbead compositions include microbeads of a biodegradable material and vesicular agents located within or associated with the biodegradable material of the microbeads. The vesicular agents include a lipid bilayer and comprise liposomes or ethosomes. The drug-loaded microbeads include a first therapeutic agent associated with the vesicular agents, and a second therapeutic agent different from the first therapeutic agent. The vesicular agents include a lipid bilayer surrounding a vesicular core. The second therapeutic agent is contained within the microbeads or associated with the microbeads through ionic or non-covalent interaction and may or may not be associated with the vesicular agents. Drug-loaded biodegradable microbead compositions include microbeads of biodegradable material and a therapeutic agent.

Abstract: Medical devices such as stents, stent grafts, and balloon catheters include a coating layer applied over a modified exterior surface of the medical device. The modified exterior surface comprises an exterior surface of the medical device subjected to a surface modification that decreases a surface free energy of the exterior surface before application of the coating layer an exterior surface. The coating layer comprises a hydrophobic therapeutic agent and at least one additive. The modified exterior surface may affect the release kinetics of the drug from the device, the crystallinity of the drug layer, the surface morphology of the coating and particle shape, or the particle size of drug of a therapeutic layer in the coating layer. For example, the effects caused by the modified exterior surface may increase the retention time and amount of therapeutic agent in tissue.

Abstract: In some implementations, a system may receive, from a first user, data associated with a new database entry to be added to a master database that is associated with multiple sets of users having different access permissions to entries in the master database. The system may write the data to a first repository, write an entry including the data to a master repository, and generate a record of the entry. The system may receive, from a second user, additional data associated with the new database entry. The system may write the additional data to a second repository, modify the entry in the master repository based on the additional data, and generate a record of the modified entry. The system may perform verifications and output a notification based on the verifications. The system may further output, to a public repository, the modified entry with at least one data value removed.

Abstract: The application is to antibodies which have been labelled with polyenzymes (multiple enzymes), specifically polyperoxidases, for use in direct immunohistochemical assays of tissues. The antibodies used diagnostically may also be antibodies which are used therapeutically.

Abstract: Drug-loaded microbead compositions including a plurality of individual microbeads of a biodegradable material, a plurality of individual vesicular agents, a first therapeutic agent, and a second therapeutic agent different from the first therapeutic agent. The vesicular agents include at least one lipid bilayer surrounding a vesicular core. The first therapeutic agent is associated with the individual vesicular agents. For example, the first therapeutic agent may be contained within the individual vesicular agents or may be associated with the individual vesicular agents by ionic or non-covalent interaction. The second therapeutic agent is different from the first therapeutic agent and contained within the individual microbeads or associated with the individual microbeads through ionic or non-covalent interaction. The second therapeutic agent may or may not be associated with the individual vesicular agents.

Abstract: The present disclosure relates to transparent ready-to-use hair bleaching compositions and compositions useful for preparing the transparent ready-to-use hair bleaching compositions. The transparent ready-to-use bleaching compositions typically include: (i) one or more oxidizing agents selected from the group consisting of persulfates, perborates, percarbonates, a salt thereof, and a mixture thereof; (ii) one or more non-acrylic thickening polymers; (iii) one or more acrylic polymers; (iv) hydrogen peroxide; (v) one or more polyurethane polyethers; and (vi) water. Kits and methods for bleaching hair also disclosed.

Abstract: A semiconductor package structure includes a first redistribution layer, a plurality of conductive connectors, a chip, and an encapsulant. The first redistribution layer has a first surface and a second surface opposite to the first surface. The first redistribution layer includes at least one conductive pattern and at least one dielectric layer stacked on each other. The conductive pattern includes a plurality of landing pads, and each of the landing pads is separated from the dielectric layer. The conductive connectors are located on the first surface. Each of the conductive connectors is corresponding to and electrically connected to one of the landing pads. The chip is located on the first surface. The chip is electrically connected to the first redistribution layer. The encapsulant encapsulates the chip and the conductive connectors. A manufacturing method of a semiconductor package structure is also provided.

Abstract: A novel prophylactic therapy for cancer, as well as therapy against DNA damage, inflammation and immunosuppression involves the ?-blocker carvedilol, which is a racemic mixture consisting of two enantiomers, S- and R-carvedilol, in 1:1 ratio. S-carvedilol is a ?-blocker, with a highly potent antagonizing activity against the ?-adrenergic receptors, which is the main mechanism for the drug's pharmacological activity in treatment of high blood pressure and heart failure. Carvedilol—the racemic mixture—prevents ultraviolet radiation induced skin cancer by attenuating DNA damage, reducing inflammation and reversing immunosuppression. The non-?-blocking enantiomer R-carvedilol exhibits the same cancer preventive efficacy as the racemic carvedilol, without disturbing the cardiovascular system. Both carvedilol and R-carvedilol prevent chemical carcinogen-induced lung cancer development and lung inflammation.

Abstract: The present invention is directed electrical circuits. According to a specific embodiment, the present invention provides a variable gain amplifier that includes a first switch, which includes drain terminal coupled to an inductor. A second switch is configured in parallel to the inductor, and the resistance value of the second switch is adjustable in response to a control signal. There are other embodiments as well.

Abstract: In some implementations, a system may receive, from a first user, data associated with a new database entry to be added to a master database that is associated with multiple sets of users having different access permissions to entries in the master database. The system may write the data to a first repository, write an entry including the data to a master repository, and generate a record of the entry. The system may receive, from a second user, additional data associated with the new database entry. The system may write the additional data to a second repository, modify the entry in the master repository based on the additional data, and generate a record of the modified entry. The system may perform verifications and output a notification based on the verifications. The system may further output, to a public repository, the modified entry with at least one data value removed.

Abstract: Turning now to the drawings, systems and methods for transferring funds in accordance with embodiments of the invention are illustrated. In one embodiment, a method for conducting peer-to-peer transfers includes obtaining a cash-out request data using a fund transfer server system, wherein the cash-out request data includes target account data and fund data, the target account data includes metadata identifying a consumer account and specifies an account to which funds will be provided, and the fund data describes the funds to be provided in response to redeeming the cash-out request, generating a cash-out code based on cash-out request data using the fund transfer server system, providing the cash-out code using the fund transfer server system, obtaining cash-out code redemption data using the fund transfer server system, wherein the cash-out code redemption data identifies the provided cash-out code, and transmitting a request to provide the funds described by the fund data.

Abstract: Methods and systems are disclosed for receiving and processing data analysis expressions. A particular method includes receiving a data analysis expression at a pivot table of a spreadsheet. The data analysis expression is executed for a particular cell of the pivot table by determining a context associated with the particular cell, calculating a value of the data analysis expression based on the context, and outputting the calculated value at the particular cell.

Abstract: Disclosed herein is a method and apparatus for forming pellets in a non-ambient environment such as a strong magnetic field. The apparatus includes a die body, a die bottom, a short push pin, a long push pin, a press tube, and an extended push pin. A powder is loaded into the die body, which is then positioned in the non-ambient environment, and the powder allowed to equilibrate. A pellet is then formed by pressing on the extended push pin while the powder is in the non-ambient environment.

Abstract: Disclosed are modular anchoring adaptors that can engage with existing features of various spinal cages to help eliminate migration and/or anterior expulsion cause by the instability of the spine, such as lordosis. Such modular adaptors will desirably mate or engage with existing features to enhance anchoring within the vertebral disc space.

Abstract: Disclosed are modular anchoring adaptors that can engage with existing features of various spinal cages to help eliminate migration and/or anterior expulsion cause by the instability of the spine, such as lordosis. Such modular adaptors will desirably mate or engage with existing features to enhance anchoring within the vertebral disc space.

Abstract: Turning now to the drawings, systems and methods for transferring funds in accordance with embodiments of the invention are illustrated. In one embodiment, a method for conducting peer-to-peer transfers includes obtaining a cash-out request data using a fund transfer server system, wherein the cash-out request data includes target account data and fund data, the target account data includes metadata identifying a consumer account and specifies an account to which funds will be provided, and the fund data describes the funds to be provided in response to redeeming the cash-out request, generating a cash-out code based on cash-out request data using the fund transfer server system, providing the cash-out code using the fund transfer server system, obtaining cash-out code redemption data using the fund transfer server system, wherein the cash-out code redemption data identifies the provided cash-out code, and transmitting a request to provide the funds described by the fund data.

Abstract: Medical devices such as stents, stent grafts, and balloon catheters include a coating layer applied over a modified exterior surface of the medical device. The modified exterior surface comprises an exterior surface of the medical device subjected to a surface modification that decreases a surface free energy of the exterior surface before application of the coating layer an exterior surface. The coating layer comprises a hydrophobic therapeutic agent and at least one additive. The modified exterior surface may affect the release kinetics of the drug from the device, the crystallinity of the drug layer, the surface morphology of the coating and particle shape, or the particle size of drug of a therapeutic layer in the coating layer. For example, the effects caused by the modified exterior surface may increase the retention time and amount of therapeutic agent in tissue.